ANI Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO ANI Pharmaceuticals is Nikhil Lalwani, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.08M, bestaande uit 9.5% salaris en 90.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.92% van de aandelen van het bedrijf, ter waarde $ 21.43M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 4.2 jaar.

Belangrijke informatie

Nikhil Lalwani

Algemeen directeur

US$8.1m

Totale compensatie

Percentage CEO-salaris	9.5%
Dienstverband CEO	4.2yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

Analyse CEO-vergoeding

Hoe is Nikhil Lalwani's beloning veranderd ten opzichte van ANI Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$23m
Mar 31 2024	n/a	n/a	US$31m
Dec 31 2023	US$8m	US$764k	US$15m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$5m	US$737k	-US$50m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$7m	US$715k	-US$43m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$4m	US$199k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 8.08M ) Nikhil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.21M ).

Compensatie versus inkomsten: De vergoeding van Nikhil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Nikhil Lalwani (46 yo)

4.2yrs

Tenure

US$8,078,353

Compensatie

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.92% $ 21.4m
Stephen Carey	Senior VP of Finance & CFO	8.5yrs	US$2.58m	0.83% $ 9.3m
Chad Gassert	Senior Vice President of Corporate Development & Strategy	3yrs	US$1.90m	1.24% $ 13.9m
Christopher Mutz	Senior Vp & Head of Rare Disease	3.8yrs	US$1.91m	0.43% $ 4.8m
Ori Gutwerg	Senior Vice President of Generics	3.8yrs	US$1.94m	0.40% $ 4.4m
Muthusamy Shanmugam	Head of R&D	3yrs	geen gegevens	0.26% $ 2.9m
James Marken	Senior Vice President of Operations	8.5yrs	US$1.43m	0.60% $ 6.8m
Elizabeth Powell	Chief Compliance Officer & Head of Legal of Rare Disease	2.8yrs	geen gegevens	geen gegevens
Meredith Cook	Senior VP	2.3yrs	geen gegevens	0.29% $ 3.2m
Krista Davis	Senior VP & Chief Human Resources Officer	2.2yrs	geen gegevens	0.26% $ 2.9m
Mary Pao	Chief Medical Officer	2.8yrs	geen gegevens	geen gegevens
Thomas Rowland	Senior VP & Head of Established Brands	3yrs	geen gegevens	0.17% $ 2.0m

3.0yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANIP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.92% $ 21.4m
Muthusamy Shanmugam	Head of R&D	3yrs	geen gegevens	0.26% $ 2.9m
Patrick Walsh	Independent Chairman	6.5yrs	US$422.21k	0.38% $ 4.3m
Antonio Pera	Independent Director	4.3yrs	US$393.25k	0.16% $ 1.8m
Thomas Haughey	Independent Director	6.5yrs	US$412.21k	0.26% $ 3.0m
Jeanne Thoma	Independent Director	4.3yrs	US$395.75k	0.21% $ 2.3m
Renee Tannenbaum	Independent Director	2.7yrs	US$392.37k	0.12% $ 1.3m
Matthew Leonard	Independent Director	1.3yrs	US$470.76k	0.061% $ 687.4k

4.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANIP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

ANI Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Recent updates

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind